Where to Buy GLOW: Vendor Comparison, Benefits & Side Effects

GLOW is a blend, not a single peptide: vendors describe it as GHK-Cu, a copper-binding tripeptide, with BPC-157 and TB-500. The ratio is set by whoever compounds the vial and is not standardised across vendors. It is sold strictly as a research chemical, not approved by the FDA or any other regulator for human use, and nothing here is medical advice.

Each component has its own preclinical literature: GHK-Cu in cell culture and rodent wound models, BPC-157 in rat tendon and gut injury models, TB-500 through work on its parent protein, thymosin beta-4. The blend itself has no dedicated study base — no published pharmacology, no controlled trial, and no evidence of synergy between the three.

PeptidesFinder's role is narrower than the science. We track which research vendors list GLOW, normalise every listing to a price per milligram so vial sizes can be compared, and record whether a recent certificate of analysis is on file. The comparison below is re-checked on a schedule; confirm current pricing and the stated composition on the vendor's own site before ordering.

Everything below belongs to the individual components. GLOW itself has never been the subject of a published study, so there is no blend-level mechanism to describe — only three separate preclinical literatures that vendors have combined in a vial.

GHK-Cu: copper transport and matrix synthesis. GHK is a tripeptide isolated from human plasma that binds copper with high affinity. In cultured human dermal fibroblasts it has been reported to raise synthesis of collagen, elastin and glycosaminoglycans, and review work on cultured cells describes broad shifts in gene expression across antioxidant and repair pathways. Most in vivo healing data come from rodent and rabbit wound models. GHK-Cu is also a long-standing cosmetic ingredient, which is a regulatory category rather than evidence of a systemic effect.

BPC-157: angiogenesis and the nitric oxide system. In rat tendon, muscle and gastrointestinal injury models, BPC-157 is reported to increase expression of vascular endothelial growth factor receptor 2 and to speed new vessel formation around an injury, and to counter both nitric oxide synthase inhibition and nitric oxide over-production — which those authors describe as modulation rather than stimulation. In cultured tendon fibroblasts it has been reported to activate the FAK–paxillin pathway associated with cell migration. Controlled human trials are essentially absent.

TB-500: which molecule is in the vial is not settled. Thymosin beta-4 is a 43-amino-acid actin-sequestering protein studied for corneal, dermal and cardiac repair, and the full-length protein has been through registered clinical trials in ophthalmology. Material sold as TB-500 is described by suppliers either as full-length thymosin beta-4 or as its shorter LKKTETQ actin-binding fragment — these are not the same molecule, which is one reason a certificate of analysis for a blend should say which one it contains. Reading those ophthalmic trials onto a vendor vial is therefore an inference, not a result.

No pharmacology for the combination. There is no published pharmacokinetic work on these three peptides given together, no controlled study of the combination in any species, and no agreed ratio — two vials labelled GLOW may hold quite different amounts of each component. Any claim of synergy is an inference drawn across three separate literatures, not a finding.

Formulation is an open question. GHK-Cu carries a redox-active copper ion, and how that behaves alongside two other peptides in one lyophilised vial — stability, purity, and what a certificate of analysis on a mixture can actually attest to — has not been characterised in the published literature. A COA for a blend should identify and quantify each component, not just total peptide mass.

None of these findings establishes safety or efficacy in humans. GLOW is not approved for any medical use in any jurisdiction, and neither are its individual components.